Using Frozen vs. Continuously Cultured Cells -HTS
Tuesday, April 03, 2007, 12:00 PM Eastern Time (ET)

Many drug screens now include batch-frozen cells as reagents to uncouple an assay from cell production.  This strategy should be approached with caution, as cells can demonstrate differing growth characteristics depending upon treatment.   In this live, on-line seminar, we will discuss some differences in the performance of batch-frozen vs. continuously cultured cells in multiple assay formats

Speaker:

Michael Briggs, Ph. D., is a scientist in the Corning Life Science Applications group, where his research is focused on optimizing biochemical and cell-based assays. Michael received his B. S. in Biology from Cornell University and his Ph.D. in Microbiology and Immunology from the University of Rochester. He has completed two post-doctoral fellowships, including a fellowship at Harvard Medical School where he investigated the mechanisms regulating the pathogenesis of cancer metastasis.

We hope you will join us for this exclusive event.